89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibrob…
Biotechnology
US, San Francisco [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
89bio, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USD89bio, Inc. can't present revenue by segment